a proper update , page-11

Vitrogro is clearly a worthwhile product for the benefit of humanity, but think about this in terms of its cold commercial benefit to a partner.

According to TIS presentations, the current treatment is 50% successful, so the players can already satisfy and profit from 50% of the market with their existing product. Anything they pay for new product will only benefit them some portion beyond the first 50%.

So how good is this product at getting 100% heal results beyond 50%?

The presentations, as I understand them (and remember this is an issue of cold business statistics, not human wellbeing) suggest not much.
For example, the presentation dated 13 October 2010 indicates that 30 Australians were tested and only 5 completely healed. That's around 16% success.
So, if I read it correctly then this product will improve the current treatment from 50% success to 66% success and will partly heal another maybe 15%.

COMMERCIALLY SPEAKING, why is this of value to the "partners"? Why would they wish to pay $millions and millions for a small percentage increase?